NEW YORK (GenomeWeb) – Precipio is out of compliance with a Nasdaq listing requirement, the firm said in a document filed Friday with the US Securities and Exchange Commission.

The company said Nasdaq notified it on March 26 that for the past 30 consecutive business days, the closing bid price per share of its common stock was below the $1 minimum needed for continued listing.

Nasdaq has given Precipio a grace period until Sept. 24, 2018 to regain compliance by ensuring that its common stock price meets or exceeds $1 per share for at least 10 consecutive business days.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.